IntroductionFacilitators and barriers of adherence to disease-modifying anti-rheumatic drugs (DMARDs) have been identified by patients with inflammatory arthritis earlier. However, the relative importance from the patients' perspective of these factors is unknown. Knowledge on this ranking might guide the development of interventions and may facilitate targeted communication on adherence. This study aims to examine 1) the relative importance patients attach to facilitators and barriers for DMARDs adherence, and 2) the relationship between patient characteristics and ranking of these factors.MethodsOne hundred twenty-eight outpatients with inflammatory arthritis; (60% female, mean age 62years (SD=12), median disease duration 15years, IQR (7,...
Contains fulltext : 79858.pdf (publisher's version ) (Closed access)OBJECTIVE: Non...
Objectives Treatment non-adherence is more frequent among difficult-to-treat (D2T) than among non-D2...
Sharan K Rai,1 Alyssa Howren,1,2 Elizabeth S Wilcox,3 Anne F Townsend,1,4 Carlo A Marra,1,5 J Antoni...
IntroductionFacilitators and barriers of adherence to disease-modifying anti-rheumatic drugs (DMARDs...
Introduction Facilitators and barriers of adherence to disease-modifying anti-rheumatic drugs (DMARD...
Background: Although disease-modifying anti-rheumatic drugs (DMARDs) are the cornerstone of treatmen...
Background: Although disease-modifying anti-rheumatic drugs (DMARDs) are the cornerstone of treatmen...
Background Disease-modifying anti-rheumatic drugs (DMARDs) are the cornerstone of rheumatoid arthrit...
Introduction: Non-adherence to disease-modifying antirheumatic drugs (DMARDs) hampers the targets of...
Adherence to medication in patients with rheumatoid arthritis is low, varying from 30 to 80%. Improv...
OBJECTIVE: Nonadherence with medication treatment has been found to occur in large proportions of pa...
Contains fulltext : 79858.pdf (publisher's version ) (Closed access)OBJECTIVE: Non...
Objectives Treatment non-adherence is more frequent among difficult-to-treat (D2T) than among non-D2...
Sharan K Rai,1 Alyssa Howren,1,2 Elizabeth S Wilcox,3 Anne F Townsend,1,4 Carlo A Marra,1,5 J Antoni...
IntroductionFacilitators and barriers of adherence to disease-modifying anti-rheumatic drugs (DMARDs...
Introduction Facilitators and barriers of adherence to disease-modifying anti-rheumatic drugs (DMARD...
Background: Although disease-modifying anti-rheumatic drugs (DMARDs) are the cornerstone of treatmen...
Background: Although disease-modifying anti-rheumatic drugs (DMARDs) are the cornerstone of treatmen...
Background Disease-modifying anti-rheumatic drugs (DMARDs) are the cornerstone of rheumatoid arthrit...
Introduction: Non-adherence to disease-modifying antirheumatic drugs (DMARDs) hampers the targets of...
Adherence to medication in patients with rheumatoid arthritis is low, varying from 30 to 80%. Improv...
OBJECTIVE: Nonadherence with medication treatment has been found to occur in large proportions of pa...
Contains fulltext : 79858.pdf (publisher's version ) (Closed access)OBJECTIVE: Non...
Objectives Treatment non-adherence is more frequent among difficult-to-treat (D2T) than among non-D2...
Sharan K Rai,1 Alyssa Howren,1,2 Elizabeth S Wilcox,3 Anne F Townsend,1,4 Carlo A Marra,1,5 J Antoni...